Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PLX4032

Known as: B-Raf inhibitor PLX4032, PLX 4032, PLX-4032 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Activated RAS promotes dimerization of members of the RAF kinase family. ATP-competitive RAF inhibitors activate ERK signalling… Expand
  • figure 1
  • figure 3
  • figure 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the… Expand
  • table 1
  • table 2
  • figure 1
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Tumors with mutant BRAF and some with mutant RAS are dependent upon ERK signaling for proliferation, and their growth is… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BRAFV600E/K is a frequent mutationally active tumor‐specific kinase in melanomas that is currently targeted for therapy by the… Expand
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ∼7% of human malignancies and ∼60% of melanomas. Early… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
3534 Background: The BRAF activating mutation is present in up to 10% of metastatic colorectal carcinomas (mCRC) and is… Expand
Is this relevant?
Highly Cited
2010
Highly Cited
2010
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mutations in BRAF are common in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show… Expand
  • table 1
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
The BRAF(V600E) mutation is common in several human cancers, especially melanoma. RG7204 (PLX4032) is a small-molecule inhibitor… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?